Finally, we assessed acquisition of stem-like ALDHhiCD44+ phenotype in breast cancer cells treated with BM, tnLCM or tbLCM in the presence or absence of a neutralizing monoclonal FGF2 antibody. The gene discussed is FGF2; the disease is breast carcinoma.